139 related articles for article (PubMed ID: 38899504)
1. Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation.
Luo J; Gao Q; Tan K; Zhang S; Shi W; Luo L; Li Z; Khedr GE; Chen J; Xu Y; Luo M; Xing Q; Geng J
J Am Chem Soc; 2024 Jul; 146(26):17728-17737. PubMed ID: 38899504
[TBL] [Abstract][Full Text] [Related]
2. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
3. Lysosome-targeting chimaeras for degradation of extracellular proteins.
Banik SM; Pedram K; Wisnovsky S; Ahn G; Riley NM; Bertozzi CR
Nature; 2020 Aug; 584(7820):291-297. PubMed ID: 32728216
[TBL] [Abstract][Full Text] [Related]
4. An essential role for the Glut1 PDZ-binding motif in growth factor regulation of Glut1 degradation and trafficking.
Wieman HL; Horn SR; Jacobs SR; Altman BJ; Kornbluth S; Rathmell JC
Biochem J; 2009 Mar; 418(2):345-67. PubMed ID: 19016655
[TBL] [Abstract][Full Text] [Related]
5. Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma.
Wang C; Li Z; Zhai H; Shen X; Li F; Zhang Q; Li D; Hou H
Eur J Pharm Sci; 2024 Jul; 198():106789. PubMed ID: 38710335
[TBL] [Abstract][Full Text] [Related]
6. Lysosome and related protein degradation technologies.
Zheng H; Li G; Min J; Xu X; Huang W
Drug Discov Today; 2023 Nov; 28(11):103767. PubMed ID: 37708931
[TBL] [Abstract][Full Text] [Related]
7. Targeted Protein Degradation Mediated by Genetically Engineered Lysosome-Targeting Exosomes.
Wang T; Sun L; Ren T; Hou M; Long Y; Jiang JH; He J
Nano Lett; 2023 Oct; 23(20):9571-9578. PubMed ID: 37823825
[TBL] [Abstract][Full Text] [Related]
8. Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera).
Ji CH; Lee MJ; Kim HY; Heo AJ; Park DY; Kim YK; Kim BY; Kwon YT
Autophagy; 2022 Sep; 18(9):2259-2262. PubMed ID: 35722947
[TBL] [Abstract][Full Text] [Related]
9. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
Alabi SB; Crews CM
J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
[TBL] [Abstract][Full Text] [Related]
10. Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells.
Oh S; Kim H; Nam K; Shin I
BMB Rep; 2017 Mar; 50(3):132-137. PubMed ID: 27931517
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques.
Chen S; Cui J; Chen H; Yu B; Long S
Eur J Med Chem; 2023 Dec; 262():115911. PubMed ID: 37924709
[TBL] [Abstract][Full Text] [Related]
12. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q; Ba-Alawi W; Deblois G; Cruickshank J; Duan S; Lima-Fernandes E; Haight J; Tonekaboni SAM; Fortier AM; Kuasne H; McKee TD; Mahmoud H; Kushida M; Cameron S; Dogan-Artun N; Chen W; Nie Y; Zhang LX; Vellanki RN; Zhou S; Prinos P; Wouters BG; Dirks PB; Done SJ; Park M; Cescon DW; Haibe-Kains B; Lupien M; Arrowsmith CH
Nat Commun; 2020 Aug; 11(1):4205. PubMed ID: 32826891
[TBL] [Abstract][Full Text] [Related]
13. Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets.
Wang Y; Deng S; Xu J
Cancer Biol Med; 2020 Aug; 17(3):583-598. PubMed ID: 32944392
[TBL] [Abstract][Full Text] [Related]
14. Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis.
Guo Q; Qiu Y; Liu Y; He Y; Zhang G; Du Y; Yang C; Gao F
J Biol Chem; 2022 Nov; 298(11):102588. PubMed ID: 36243113
[TBL] [Abstract][Full Text] [Related]
15. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
16. Co-expression and prognosis analyses of GLUT1-4 and RB1 in breast cancer.
Zhang X; Pang X; Zhang Z; Liu Q; Zhang H; Xiang Q; Cui Y
BMC Cancer; 2021 Sep; 21(1):1026. PubMed ID: 34525987
[TBL] [Abstract][Full Text] [Related]
17. A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy.
Wang J; Wang Y; Yang F; Luo Q; Hou Z; Xing Y; Lu F; Li Z; Yin F
ACS Chem Biol; 2024 May; 19(5):1161-1168. PubMed ID: 38662199
[TBL] [Abstract][Full Text] [Related]
18. A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation.
Wang Q; Yang X; Yuan R; Shen A; Wang P; Li H; Zhang J; Tian C; Jiang Z; Li W; Dong S
Nat Commun; 2024 Feb; 15(1):1663. PubMed ID: 38396109
[TBL] [Abstract][Full Text] [Related]
19. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
[TBL] [Abstract][Full Text] [Related]
20. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
